Table 2 Main characteristics of MCI-AD/AD-dem and PD patients

Age (years)

72 ± 5.6; 72 (58–83)

72.2 ± 5.6; 72.5 (62–82)

71.9 ± 6; 72 (58–83)

68.3 ± 7.5; 68 (55–86)

0.032

Female/male

1.4 (42/30)

1.25 (20/16)

1.6 (22/14)

1.5 (18/12)

0.797

Disease duration (years)

2.6 ± 1.9; 2 (0.2–7)

2.4 ± 1.4; 2 (0.5–5)

2.8 ± 1.9; 3 (0.2–7)

7 ± 9.4; 3 (0.5–35)

0.004

MMSE baseline

19.9 ± 4; 20.9 (3.2–30)

22.5 ± 4; 22.4 (10.2–30)

16.8 ± 5.3; 18.4 (3.2–25.3)

24.1 ± 4.6; 25.2 (13.2–30)

< 0.001

MMSE follow-up

17.4 ± 5.7; 17.5 (1.4–26.3)

19.1 ± 5.7; 18.7 (7.4–26.3)

14.8 ± 6.3; 15.3 (1.4–25)

22.9 ± 6; 25.3 (13.9–26.9)

0.043

ΔMMSE

4.9 ± 4.9; 3.7 (−5.9–16.6)

4.2 ± 4.9; 3.2 (−2.7–16.6)

6.3 ± 6.9; 6.6 (−5.9–16)

2.2 ± 3; 1.6 (−0.4–6.1)

0.346

Follow-up time (years)

2.3 ± 1.2; 2.1 (0.1–16.6)

4.2 ± 4.9; 3.2 (2.7–16.6)

2.2 ± 1.6; 2.1 (0.1–5.1)

1.4 ± 1.8; 0.6 (0.3–4)

0.439

H&Y

–

–

–

2 ± 1; 2 (1–4)

–

UPDRS III

–

–

–

28.2 ± 18.8; 25 (10.5–78)

–

CSF NfL (pg/ml)

1003 ± 484; 920 (391–3272)

906 ± 327; 919 (391–1936)

1099 ± 591; 923 (448–3272)

622 ± 461; 503 (171–2577)

0.003